Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245284 | 0.86 | BACE1 (0.40) | HTTMEN1KMT2ALMNAMAPT | |
| SCHEMBL22283040 | 0.86 | BACE1 (0.40) | HTTMEN1KMT2ALMNAMAPT | |
| SCHEMBL22283041 | 0.86 | BACE1 (0.40) | HTTMEN1KMT2ALMNAMAPT | |
| SCHEMBL19239617 | 0.86 | BACE1 (0.40) | HTTMEN1KMT2ALMNAMAPT | |
| SCHEMBL14862556 | 0.86 | HTT (0.43) | HTTMEN1KMT2ATP53MAPT | |
| SCHEMBL17593772 | 0.86 | HTT (0.43) | HTTMEN1KMT2ATP53MAPT | |
| SCHEMBL23286091 | 0.85 | HTT (0.41) | HTTMEN1KMT2ALMNACA2 | |
| SCHEMBL22815478 | 0.85 | MEN1 (0.56) | MEN1KMT2ACA2 | |
| SCHEMBL19391315 | 0.85 | MEN1 (0.56) | MEN1KMT2ACA2 | |
| SCHEMBL19277932 | 0.85 | MEN1 (0.56) | MEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | HTT 1453/4885MEN1 930/4885KMT2A 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.